26 results
Phase A:Primary objective: Determining the feasibility of gemcitabine as a radiosensitizer in DIPG Secondary objective: Evaluation of efficacy in terms of clinical and radiological response rate and progression free survivalTertiary objectives:…
The primary objective is to investigate the safety and efficacy of LDE225 with respect to overall response rate according to independent central review (ICR).The key secondary objective is to assess LDE225 with respect to progression-free survival (…
Primary objectives: Part I: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake. Part II: 89Zr-GC1008 PET imaging in patients with…
The objectives of this study are to assess the penetration of RO532441 into recurrent GBM by 89Zr-RO5323441 PET imaging and to quantify its uptake, to visualize and quantify 89Zr-RO5323441 organ distribution, and to measure effect of bevacizumab…
The aim of this study if PET using [18F] fluorothymidine (FLT), an imaging biomarker, performed at week 10 of concomitant radio/chemotherapy for patients with newly diagnosed GBM is superior to MRI at 10 weeks to evaluate treatment response and to…
Determine whether temozolomide given during radiation therapy followed by the combination of temozolomide and CCNU as adjuvant therapy results in an improvement in event-free survival compared to historical control cohorts.To further assess the…
To establish the safety, feasibility and quality of life in children with recurrent of progressive pontine glioma who receive a ketogenic diet during a study period of 3 months
Primary Objective is to study the anti-tumor activity of the combination bevacizumab and metronomic dose temozolomide in patients with recurrent high grade gliomas. Secondary Objective is to investigate the effects of dexamethasone and bevacizumab…
Bevacizumab, Radiotherapy and Temozolomide Safety study in biopsied or resected primary GBM patients
Primary objective is determination of safety of combination of standard treatment with 3 bevacizumab infusions, followed by the standard adjuvant cycles of temozolomide. Secondary objectives: determination of: efficacy, classical response end-points…
This study investigate if, compared with the literature, an increased dosis of 70 Gy in 7 weeks will improve disease free survival against acceptable toxicity.
Primary objective:• To determine the efficacy of selinexor in adults with recurrent GBM asdetermined by the 6-months progression-free survival (6mPFS) rateSecondary objectives:• To determine the efficacy of selinexor in adults with recurrent GBM…
Primary objective* To evaluate the efficacy in terms of overall survival (OS) of erlotinib, everolimus and dasatinib in combination with radiation therapy, in patients with a DIPG both: - compared to the other experimental treatments by comparisons…
Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with brain tumors
This study has been transitioned to CTIS with ID 2024-517575-20-00 check the CTIS register for the current data. This study proposes a safety study in children in which tumors are operated on using fluorescence-guided resection which are similar to…
This study has been transitioned to CTIS with ID 2022-502668-20-00 check the CTIS register for the current data. PHASE 1 OBJECTIVES:Primary:To determine the safety of oral larotrectinib , including dose-limiting toxicity (DLT), in pediatric patients…
This study has been transitioned to CTIS with ID 2024-510767-30-00 check the CTIS register for the current data. 1. To determine the feasibility of SGM-101 for intraoperative imaging of colorectal brain metastases - Concordance between fluorescent…
This study has been transitioned to CTIS with ID 2023-503684-42-00 check the CTIS register for the current data. Main Study Objective• To confirm the dose and assess response to single agent 177Lutetium-DOTATATE treatmentin patients with relapsed or…
This study has been transitioned to CTIS with ID 2024-510691-20-00 check the CTIS register for the current data. The primary objective of Arm 1 is to evaluate the overall response rate (ORR) as determined by an independent radiology review committee…
This study has been transitioned to CTIS with ID 2023-507598-16-00 check the CTIS register for the current data. Primary objectives:Cohorts 1 and 2Maintenance Arm(s) Combinations:-To assess efficacy of combination therapy with ONC201 and novel agent…
Main objective: To determine the efficacy of pemigatinib in participants with recurrent GBM with an activating FGFR1-3 mutation or fusion/rearrangement. Secondary objectives: 1. To determine the efficacy of pemigatinib in participants with recurrent…
Primary objective:To determine the MTD/recommended dose for further study of oral LOXO-292 in patients with advanced solid tumors, including RET-fusion NSCLC, MTC, and other tumors with increased RET activity.Secondary objectives:* To determine the…